AMD-070 Hydrochloride: Potent, Selective CXCR4 Antagonist for Anti-HIV Research

Executive Summary: AMD-070 hydrochloride (SKU A3174) is a potent, selective antagonist of the CXCR4 chemokine receptor, widely used in anti-HIV and oncology research (APExBIO). It disrupts HIV entry by blocking CXCL12-CXCR4 interactions, directly affecting viral uptake and cell signaling (Turner et al., 2022). The compound is highly soluble (≥45.9 mg/mL in water) and demonstrates 98% purity, supporting rigorous cell-based and biochemical assays. Its specificity for CXCR4 over other chemokine receptors ensures minimal off-target effects. AMD-070 hydrochloride is research-grade and not approved for diagnostic or clinical use.

Biological Rationale

The CXCR4 receptor is a G-protein coupled chemokine receptor involved in immune cell trafficking, hematopoiesis, and organogenesis (Turner et al., 2022). CXCR4 plays a central role in HIV-1 infection by mediating viral entry into CD4+ T cells through its natural ligand, CXCL12 (also called SDF-1). Selective CXCR4 antagonists, such as AMD-070 hydrochloride, are essential for studying viral entry mechanisms, tumor metastasis, and immune cell migration (see prior review). This article extends previous discussions by providing updated solubility and workflow parameters.

Mechanism of Action of AMD-070 hydrochloride

AMD-070 hydrochloride binds competitively to the CXCR4 receptor on the cell surface, inhibiting its interaction with CXCL12/SDF-1. This binding prevents the conformational changes required for HIV-1 envelope glycoprotein (gp120) to mediate membrane fusion and viral entry. The inhibition is highly selective: AMD-070 displays minimal affinity for other chemokine receptors, reducing off-target effects (APExBIO). In cell-based assays, this blockade results in abrogation of CXCR4-mediated signaling events, including calcium flux and chemotaxis.

Evidence & Benchmarks

• AMD-070 hydrochloride exhibits high solubility: ≥45.9 mg/mL in water, ≥33.33 mg/mL in DMSO, and ≥50 mg/mL in water, facilitating preparation of concentrated stock and working solutions (product datasheet).
• The compound achieves 98.00% purity by HPLC, supporting reproducible performance in bioassays (APExBIO).
• AMD-070 hydrochloride blocks CXCR4-mediated HIV-1 entry by disrupting gp120-CXCR4 binding (Turner et al., 2022, DOI).
• It has negligible activity against CYP2C6 and CYP2C9, distinguishing it from classical inhibitors like sulfaphenazole (Turner et al., 2022).
• Long-term storage of AMD-070 hydrochloride solutions is not recommended; fresh preparation ensures maximal potency (APExBIO).

Applications, Limits & Misconceptions

AMD-070 hydrochloride is employed in studies of HIV-1 entry, migration, and invasion, and as a research tool for dissecting CXCR4 signaling in cancer and stem cell biology (see related analysis). Unlike broad-spectrum chemokine antagonists, AMD-070 provides precision in targeting the CXCR4 axis. This article clarifies its solubility and selectivity profiles, updating prior coverage of cytotoxicity and viability assays (compare here).

Common Pitfalls or Misconceptions

• AMD-070 hydrochloride is not active against other chemokine receptors such as CCR5 and should not be used as a pan-chemokine inhibitor.
• The compound is for research use only; it is not approved for human or veterinary clinical applications.
• Prolonged storage of working solutions (>24 hours) at room temperature or 4°C leads to potency loss; always prepare fresh aliquots.
• It does not inhibit CYP2C6 or CYP2C9; thus, it is not suitable for studies requiring cytochrome P450 inhibition (Turner et al., 2022).
• Solubility may decrease in highly acidic or basic buffers; verify solution clarity before use.

Workflow Integration & Parameters

For optimal results, researchers should dissolve AMD-070 hydrochloride in water or DMSO at concentrations up to 45.9 mg/mL and 33.33 mg/mL, respectively. The stock solution should be prepared immediately prior to use and stored at -20°C for no longer than one week. In cellular assays, typical working concentrations range from 0.1 to 10 μM. Assay buffers should be neutral pH to preserve stability. The product is supplied by APExBIO with a certificate of analysis guaranteeing ≥98% purity (A3174 kit).

Conclusion & Outlook

AMD-070 hydrochloride remains a reference standard for selective CXCR4 inhibition in anti-HIV and oncology research. Its high solubility, purity, and specificity allow for robust and reproducible experimental designs. Future studies may extend its use to novel models of CXCR4-driven pathology. For detailed technical guidance and validated protocols, visit the product page.